EARLY SWITCH THERAPY APPROACH FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE

被引：0
|
作者：
Shukhov, O. [1 ]
Chelysheva, E. [1 ]
Gusarova, G. [1 ]
Abdullaev, A. [2 ]
Sudarikov, A. [2 ]
Obukhova, T. [2 ]
Turkina, A. [1 ]
机构：
[1] Sci & Advisory Dept Chemotherapy Myeloproliferat, Moscow, Russia
[2] Hlth Minist Russian Federat, Fed State Budgetary Inst Hematol Res Ctr, Moscow, Russia
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1559
引用
收藏
页码：604 / 604
页数：1
相关论文
共 50 条
  • [31] Optimizing Therapy for Patients With Chronic Myelogenous Leukemia in Chronic Phase
    Kantarjian, Hagop M.
    Cortes, Jorge
    La Rosee, Paul
    Hochhaus, Andreas
    CANCER, 2010, 116 (06) : 1419 - 1430
  • [32] MEAN CORPUSCULAR VOLUME CAN BE AN EARLY PREDICTOR FOR MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Ozkan, M. Comert
    Kaya, E.
    Cirik, S.
    Kuku, I.
    Erkurt, M.
    LEUKEMIA RESEARCH, 2017, 61 : S28 - S28
  • [33] Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia
    Verstovsek, S
    Kantarjian, H
    Manshouri, T
    O'Brien, S
    Faderl, S
    Talpaz, M
    Cortes, J
    Albitar, M
    CANCER, 2002, 94 (05) : 1517 - 1521
  • [34] Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
    Kiguchi, Toru
    Tauchi, Tetsuzo
    Ito, Yoshikazu
    Miyazawa, Keisuke
    Kimura, Yukihiko
    Ohyashiki, Kazuma
    LEUKEMIA RESEARCH, 2009, 33 (03) : 506 - 508
  • [35] MICRORNAS EXPRESSION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE
    Fallah, Parviz
    Zamanizadeh, Ayeh
    Obeidi, Narges
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 37 - 37
  • [36] Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia
    Poe-Hirr Hsyu
    Diane R. Mould
    Richard N. Upton
    Michael Amantea
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 209 - 218
  • [37] DASATINIB FRONTLINE IN ELDERLY PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA
    Stagno, F.
    Breccia, M.
    Annunziata, M.
    Trawinska, M.
    Iurlo, A.
    Sgherza, N.
    Fava, C.
    Gozzini, A.
    Luciano, L.
    Bonifacio, M.
    Sora, F.
    Crescenzi, S. Leonetti
    Bocchia, M.
    Crugnola, M.
    Gugliotta, G.
    Capodanno, I.
    Galimberti, S.
    Feo, C.
    Porrini, R.
    Pregno, P.
    Tiribelli, M.
    Rizzo, M.
    Mauro, E.
    Antolino, A.
    Rossi, A. Russo
    Guarini, A.
    Abruzzese, E.
    Vigneri, P.
    Latagliata, R.
    HAEMATOLOGICA, 2017, 102 : 90 - 91
  • [38] Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase
    Takahashi, Naoto
    Miura, Masatomo
    PHARMACOLOGY, 2011, 87 (5-6) : 241 - 248
  • [39] CLINICAL ASPECTS OF NILOTINIB USE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE
    Gusarova, G. A.
    Turkina, A. G.
    Kolosheinova, T. I.
    Vakhrusheva, M. V.
    Chelysheva, E. Yu.
    Zakharova, E. S.
    Kuznetsov, S. V.
    Nemchenko, I. S.
    Sokolova, M. A.
    Goryacheva, S. R.
    Lazareva, O. V.
    Bykova, A. V.
    Tkhai, N. V.
    Khoroshko, N. D.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2012, 57 (04): : 3 - 11
  • [40] Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase
    Kantarjian, Hagop M.
    Larson, Richard A.
    Guilhot, Francois
    O'Brien, Stephen G.
    Mone, Manisha
    Rudoltz, Marc
    Krahnke, Tillmann
    Cortes, Jorge
    Druker, Brian J.
    CANCER, 2009, 115 (03) : 551 - 560
12345